TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 93 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q3 2018. The put-call ratio across all filers is 5.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $10,000 | 0.0% | 21,121 | +125.9% | 0.00% | 0.0% |
| Q4 2018 | $10,000 | -73.0% | 9,349 | -29.7% | 0.00% | -66.7% |
| Q3 2018 | $37,000 | +60.9% | 13,305 | +286.5% | 0.00% | +50.0% |
| Q3 2017 | $23,000 | +1050.0% | 3,442 | +1287.9% | 0.00% | – |
| Q4 2015 | $2,000 | -96.8% | 248 | -97.1% | 0.00% | -100.0% |
| Q3 2015 | $63,000 | +530.0% | 8,428 | +4093.0% | 0.01% | +500.0% |
| Q2 2015 | $10,000 | -80.4% | 201 | -85.5% | 0.00% | -83.3% |
| Q1 2015 | $51,000 | +2450.0% | 1,385 | +2615.7% | 0.01% | – |
| Q4 2014 | $2,000 | -60.0% | 51 | -88.1% | 0.00% | -100.0% |
| Q1 2014 | $5,000 | -44.4% | 430 | -36.0% | 0.00% | -50.0% |
| Q4 2013 | $9,000 | -84.7% | 672 | -87.0% | 0.00% | -66.7% |
| Q3 2013 | $59,000 | -38.5% | 5,154 | -61.9% | 0.01% | -25.0% |
| Q2 2013 | $96,000 | – | 13,537 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVEY CAPITAL MANAGEMENT INC | 354,300 | $7,068,000 | 2.77% |
| Opaleye Management Inc. | 169,700 | $3,385,515,000 | 2.64% |
| Broadfin Capital, LLC | 959,247 | $19,137,000 | 2.01% |
| Novo Holdings A/S | 900,000 | $17,955,000 | 1.75% |
| Eventide Asset Management | 300,900 | $6,003,000 | 0.84% |
| EAM Investors, LLC | 152,595 | $3,044,000 | 0.62% |
| COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT | 497,858 | $9,932,000 | 0.51% |
| Granite Point Capital Management, L.P. | 40,000 | $798,000 | 0.40% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,191 | $8,981,000 | 0.33% |
| TFS CAPITAL LLC | 133,070 | $2,655,000 | 0.23% |